A Diagnostic Analysis Workflow to Optimal Multiple Tumor Markers to Predict the Nonmetastatic Breast Cancer from Breast Lumps

Table 2

Comparison of plasma biomarkers levels in breast cancer patients and benign breast disease patients.

Markers	Mean ± SD		value	Fold change
	Breast cancer	Benign breast disease
CEA (ng/mL)	2.58 ± 5.24	1.47 ± 0.87	0.002	1.76
Ca 15-3 (U/mL)	12.84 ± 6.9	9.2 ± 3.98	0.000	1.4
CYFRA 21-1 (ng/mL)	2.59 ± 1.46	1.66 ± 0.71	0.000	1.55
AFP (IU/mL)	2.86 ± 1.64	2.41 ± 1.18	0.030	1.19
FERR (ng/mL)	102.81 ± 75.45	63.2 ± 51.52	0.000	1.63
Ca 12-5 (U/mL)	14.39 ± 10.97	15.17 ± 8.66	0.192	0.95
Ca 72-4 (U/mL)	3.8 ± 4.07	3.15 ± 3.39	0.237	1.21
NSE (ng/mL)	12.21 ± 2.95	12.05 ± 2.82	0.667	1.01

values are calculated from the Wilcoxon rank-sum test.